Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Avalo Therapeutics (C6K0) Stock Price & Analysis

0 Followers

C6K0 Stock Chart & Stats

€6.34-€0.13(-2.01%)
At close: 5:30 PM GMT+1
€0€500€1KAug 23Oct 2Oct 25Oct 8Oct 27
Day’s Range
EUR 6.22 - EUR 6.34
52-Week Range
EUR 5.84 - EUR 19.32
Previous Close
EUR 6.47
Volume
N/A
Average Volume (3M)
3
Market Cap
EUR 349.24M
Enterprise Value
EUR 407.68M
Total Cash (Recent Filing)
EUR 400.28M
Total Debt (Recent Filing)
EUR 242.00K
Price to Earnings (P/E)
―
Beta
0.74
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-0.52
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Current Leverage

Low current leverage reduces near-term solvency pressure and preserves more financial flexibility than a heavily indebted development-stage biotech would have. This may help AVTX direct available resources toward clinical programs and manage obligations while it works toward future revenue generation.

Biotech Pipeline Model

The company is focused on a defined therapeutic area with multiple investigational development paths rather than relying on a mature product franchise. Successful clinical advancement could create future commercialization or partnering opportunities, providing a durable route to value creation.

Improved Equity Base

A substantially higher recent equity base provides a stronger capital foundation than the company had during earlier periods that included negative equity. Although it does not eliminate financing risk, the improvement can support continued development and reduce immediate balance-sheet fragility.

Bears Say

Sharp Revenue Decline

Sharp historical revenue contraction and minimal current revenue show that AVTX has not yet established a dependable commercial income stream. Continued dependence on investigational programs makes financial performance highly sensitive to clinical progress and delays the ability to fund operations internally.

Deep Operating Losses

Large operating and net losses indicate that the current business model is far from covering its cost base. Persistently negative margins reduce resilience, consume capital that could otherwise support development, and leave future profitability dependent on successful pipeline advancement or meaningful revenue scaling.

Persistent Cash Burn

Sustained negative operating and free cash flow means AVTX is consuming cash rather than self-funding its research and operations. Unless spending falls or revenue scales materially, continued external financing may be required, creating ongoing dilution and funding risk.

Avalo Therapeutics News

C6K0 FAQ

What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was €5.84 and its highest was €19.32 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Avalo Therapeutics’s market cap is €349.24M.
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 1 day.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.738 earnings per share for the quarter, missing the consensus estimate of -€0.519 by -€0.22.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 53,629,990 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -€0.738 in its last earnings report, missing expectations of -€0.519. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Hedge funds hold Avalo Therapeutics shares: the largest hedge-fund position in Avalo Therapeutics is 666,932,551 shares, and hedge funds increased their holdings by 2.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology